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HIGHLIGHTS
This study evaluated cardiac energy production and bioenergetics in an experimental model of diabetes treated with the SGLT2 inhibitor empagliflozin.
Rates of glucose oxidation, fatty acid oxidation, ketone oxidation, glycolysis, and cardiac function were measured in diabetic (db/db) mice treated with or without empagliflozin.
Rates of glucose and ketone oxidation in the hearts of untreated db/db mice were markedly decreased, whereas fatty acid oxidation was increased with a significant overall reduction in cardiac ATP production compared to nondiabetic mice.
Empagliflozin treatment increased overall cardiac ATP production by w30% and prevented cardiac failure; this effect was due to an increase in the rate of glucose and fatty acid oxidation, but with no a change in the rate of ketone oxidation.
The authors conclude that the SGLT2 inhibitor empagliflozin enhances the cardiac energy pool by increasing cardiac energy production from glucose and fatty acid oxidation, but not ketone oxidation. 
SUMMARY
SGLT2 inhibitors have profound benefits on reducing heart failure and cardiovascular mortality in individuals with type 2 diabetes, although the mechanism(s) of this benefit remain poorly understood. Because changes in cardiac bioenergetics play a critical role in the pathophysiology of heart failure, the authors evaluated cardiac energy production and substrate use in diabetic mice treated with the SGTL2 inhibitor, empagliflozin. Empagliflozin treatment of diabetic db/db mice prevented the development of cardiac failure. Glycolysis, and the oxidation of glucose, fatty acids and ketones were measured in the isolated working heart perfused with 5 mmol/l glucose, 0.8 mmol/l palmitate, 0.5 mmol/l ß-hydroxybutyrate (ßOHB), and 500 mU/ml insulin. In vehicle-treated db/db mice, cardiac glucose oxidation rates were decreased by 61%, compared with control mice, but only by 43% in empagliflozin-treated diabetic mice. Interestingly, cardiac ketone oxidation rates in db/db mice decreased to 45% of the rates seen in control mice, whereas a similar decrease (43%) was seen in empagliflozin-treated db/db mice. Overall cardiac adenosine triphosphate (ATP) production rates decreased by 36% in db/db vehicle-treated hearts compared with control mice, with fatty acid oxidation providing 42%, glucose oxidation 26%, ketone oxidation 10%, and glycolysis 22% of ATP production in db/db mouse hearts. In empagliflozin-treated db/db mice, cardiac ATP production rates increased by 31% compared with db/db vehicletreated mice, primarily due to a 61% increase in the contribution of glucose oxidation to energy production.
Cardiac efficiency (cardiac work/O 2 consumed) decreased by 28% in db/db vehicle-treated hearts, compared with control hearts, and empagliflozin did not increase cardiac efficiency per se. Because ketone oxidation was impaired in db/db mouse hearts, the authors determined whether this contributed to the decrease in cardiac efficiency seen in the db/db mouse hearts. Addition of 600 mmol/l ßOHB to db/db mouse hearts perfused with 5 mmol/l glucose, 0.8 mmol/l palmitate, and 100 mU/ml insulin increased ketone oxidation rates, but did not decrease either glucose oxidation or fatty acid oxidation rates. The presence of ketones did not increase cardiac efficiency, but did increase ATP production rates, due to the additional contribution of ketone oxidation to energy production. The authors conclude that empagliflozin treatment is associated with an increase in ATP production, resulting in an enhanced energy status of the heart. A separate group of C57BL/6J and db/db mice was treated with a single 10 mg/kg dose of empagliflozin via oral gavage before being subjected to a 24-h fast.
Lastly, 23-week-old naive male db/db mice were used to study the short-term effects of ketones on the db/db mouse heart.
TRANSTHORACIC ECHOCARDIOGRAPHY. The cardiac function of anesthetized (3% isoflurane) mice was assessed with a Vevo 3100 high-resolution imaging system that was coupled to a 30-MHz transducer (RMV-707B; VisualSonics, Toronto, Canada). Systolic and diastolic parameters were assessed as previously described (25) .
BLOOD METABOLITE LEVELS. For both fed and fasted protocols, total plasma ketones levels were measured using a 2-part kit from Wako Diagnostics (Cat: 415-73301 and 411-73491, Wako Diagnostics, Mountain View, California), blood glucose levels were measured using a glucometer, and plasma fatty acid levels were measured using a kit from Roche (Cat: 11383175001, Roche, Basel, Switzerland).
ISOLATED WORKING HEART PERFUSION. Male 22-week to 23-week-old db/db mice and age-matched control C57BL/6J mice were sacrificed with sodium pentobarbital after their hearts were excised and blood collected for plasma isolation. The hearts were perfused for 60 min in the isolated working mode as previously described (26) Verma et al. IMMUNOPRECIPITATION. Lysates (300 mg) were pre-cleared with 20 ml of protein A/G agarose beads, incubated overnight at 4 C with anti-acetyl lysine (2 ml/300 mg lysate, EMD Millipore, catalog AB3879; MilliporeSigma) before the acetylated proteins were pulled down with A/G agarose beads (15) . The heavy chain of IgG was used as the loading control.
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MYOCARDIAL MALONYL-CoA LEVELS. An assay to determine malonyl-CoA levels from frozen myocardial tissue was performed based on a previously described modified ultra high-pressure liquid chromatography procedure (27) .
STATISTICAL ANALYSIS. The data are presented as mean AE SEM and were either analyzed by one-way analysis of variance (ANOVA) and the least significant difference post hoc test or repeated one-way ANOVA and the least significant difference post hoc test.
A p value of <0.05 was considered significant. 
were significantly lighter than the db/db mice ( Figure 1A ). Empagliflozin treatment did not appreciably affect the weights of db/db mice. Ventricular mass, a surrogate measurement of hypertrophy, was higher for vehicle-treated db/db mice relative to that for C57BL/6J mice. As shown in Figure 1B , mean ventricular mass for empagliflozin-treated db/db mice was lower than that for vehicle-treated db/db mice and comparable to that for C57BL/6J mice. Empagliflozin significantly lowered fasting blood glucose levels ( Table 1) . Although plasma ketone levels in the vehicle-treated fed and fasted db/db mice were not different from those of the C57BL/6J mice, significantly higher levels of fed and fasted ketone levels were detected in the empagliflozin-treated db/db mice ( Table 1) . Free fatty acid levels, generally higher in db/db mice relative to C57BL/6J mice, were unaffected by empagliflozin treatment ( Table 1) .
Cardiac function, as measured in the isolated working heart model, was significantly compromised in the hearts of db/db mice when compared with that of hearts from C57BL/6J mice ( Figures 1C and 1D ). This agrees with previous reports (28, 29 hearts ( Figure 2C ). As shown in Figure 2D , the mean cardiac ketone oxidation rate in the hearts of db/db mice was approximately 43% lower than that for hearts from C57BL/6J mice ( Figure 2D) . Notably, this outcome was apparent regardless of whether insulin was present or not. Of further interest is the observation that empagliflozin had no influence on the ketone oxidation rates of hearts from db/db mice ( Figure 2D ).
Overall cardiac ATP production rates in the hearts of vehicle-treated db/db mice were 36% lower than those measured in the C57BL/6J mice, with fatty acid oxidation providing 42%, glucose oxidation 26%, ketone oxidation 10%, and glycolysis 22% of energy production in the presence of insulin ( Figure 2E ). In empagliflozin-treated db/db mice, cardiac ATP production rates increased by 31%, such that they were restored to levels similar to those measured for the hearts from C57BL/6J mice ( Figure 2E ).
Cardiac efficiency (cardiac work/O 2 consumed)
decreased by 28% in the hearts of vehicle-db/db mice compared with that of the hearts from vehicle-treated C57BL/6J mice ( Figure 2F ). Under our experimental 
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FIGURE 2 Absolute Metabolic Rates and Cardiac Efficiency in Ex Vivo Isolated Working Hearts From Empagliflozin-Treated db/db Mice
Metabolic rates are shown for palmitate oxidation (n ¼ 8 to 10/group) (A), glucose oxidation (n ¼ 8 to 10/group) (B), glycolysis (8 to 9/group) (C), b-hydroxybutyrate (bOHB) oxidation (n ¼ 8 to 9/group) (D), and total adenosine triphosphate (ATP) production (8 to 10/group) (E). Cardiac efficiency calculated as cardiac work/O 2 consumed (n ¼ 9 to 12/group) (F) is also shown. Data are presented as mean AE SEM. Data were analyzed by 1-way ANOVA to determine differences within the same insulin status and between groups in the presence or absence of insulin followed by LSD post hoc test. Four separate 1-way ANOVAs were performed to determine each substrate's contribution to ATP production. Cardiac efficiency was analyzed by repeated 1-way ANOVA followed by LSD post hoc test. *p < 0.05 was considered as a significantly different comparison with C57BL/6J þ Vehicle. For E, ‡p < 0.05 was considered as a significantly different in comparison with C57BL/6J þ Vehicle within the same insulin status. Abbreviations as in Figure 1 . Working heart perfusion derived palmitate (fatty acid) oxidation (n ¼ 7 for db/db, n ¼ 6 for db/db þ 600 mM bOHB) (A), glucose oxidation (n ¼ 5 for db/db, n ¼ 8 for db/db þ 600 mM bOHB) (B), and glycolysis (n ¼ 4 to 5 for db/db, n ¼ 7 to 8 for db/db þ 600 mM bOHB) (C) levels. bOHB (ketone body) oxidation levels (n ¼ 8 for db/db þ 600 mM bOHB) (D) are also shown. Cardiac ATP production and comparison between contribution from glycolysis and the oxidation of glucose, palmitate, and bOHB (n ¼ 5 to 8 for all groups) (E). Cardiac efficiency of the ex vivo heart as determined by normalizing cardiac work to oxygen consumption (n ¼ 10 for db/db, n ¼ 15 for db/db þ 600 mM bOHB) (F) . Data are presented as mean AE SEM. Data were analyzed by 1-way ANOVA followed by LSD post hoc test. Three separate 1-way ANOVAs were performed to determine each substrate's contribution to ATP production. *p < 0.05 was considered as a significantly different comparison to the insulin-absent levels of the same group. For E, ‡p < 0.05 was considered as significantly different in comparison with the same group in the absence of insulin.
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Abbreviations as in Figures 1 and 2 . In db/db mice treated with 600 mmol/l bOHB, there was an insulin-dependent increase in glucose oxidation, accompanied with a drop in palmitate oxidation ( Figures 3A and 3B ). The addition of 600 mmol/l bOHB to isolated perfused hearts from db/db mice did not affect palmitate oxidation, glucose oxidation, or glycolysis ( Figures 3A and 3C) . However, addition of bOHB resulted in increased ketone oxidation ( Figure 3D) , which was independent of insulin.
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Interestingly, the addition of bOHB increased total energy (ATP) production ( Figure 3E shown previously, we observed that the decline in cardiac function in db/db mice was associated with a reduction in cardiac ATP production. This was due to a combined decrease in glucose oxidation and fatty acid oxidation rates (17) . We also provide the novel observation that ketone oxidation is dramatically inhibited in the db/db mouse heart, contributing to the decrease in ATP production in these hearts. It is well known that in diabetes, decreased insulin stimulation of glucose oxidation in the failing heart contributes to both an impairment of heart efficiency and the development of cardiac failure (12, (17) (18) (19) . In support of this concept, we have demonstrated that the low glucose oxidation rates in the db/db mouse hearts was accompanied by a decrease in cardiac efficiency. We also observed that compared with the hearts of C57BL/6J mice, db/db mouse hearts had an w36% reduction in cardiac ATP production, with fatty acid oxidation providing 42%, glucose oxidation 26%, ketone oxidation 10%, and glycolysis 22% of total ATP production. By contrast, in empagliflozin-treated db/db mice, cardiac ATP production rates increased by 31% compared with vehicle-treated db/db mice.
This was not accompanied by a significant change in overall cardiac efficiency, suggesting that the cardiac benefits associated with empagliflozin were associated with an increase in cardiac ATP production.
Furthermore, when db/db mouse hearts were perfused with higher ketone levels (which was seen in vivo with empagliflozin treatment), overall cardiac ATP production was increased, supporting the
concept that the beneficial effects of empagliflozin are associated with an increased ATP production in the heart.
Of note, rates of ketone oxidation were markedly depressed in db/db mouse hearts. Intriguingly, this phenomenon did not seem to be responsible for the observed decrease in cardiac efficiency because infusion of db/db hearts with bOHB did not change the rates of either glucose or fatty acid oxidation.
Importantly, exogenous bOHB infusion was associated with an overall increase in ATP production in db/db mouse hearts, not through changes in glucose or fatty acid oxidation, but rather via an independent increase in ATP production through ketone oxidation.
Finally, empagliflozin treatment did not affect the rates of ketone oxidation in db/db hearts. Taken together, these data suggest that empagliflozin treatment is associated with an increase in overall A decrease in the glucose oxidation contribution to ATP production was evident in the db/db mouse hearts. The decrease in glucose oxidation did not appear to be due to an increase phosphorylation and inhibition of PDH, the rate-limiting enzyme for glucose oxidation ( Figure 4B ). The decreased glucose oxidation was also not the result of an increased acetylation of PDH ( Figure 4H ) (which inhibits PDH [32] and glucose oxidation). Rather, it appears the decrease in glucose oxidation observed in db/db mouse hearts was due to an increased expression of fatty acid oxidative enzymes ( Figures 4D and 4E ), which would decrease glucose oxidation secondary to an increase in fatty acid oxidation (i.e., the Randle
Cycle [33] ). Interestingly, the permissive effect empagliflozin exerts on ATP production from glucose oxidation did not appear to result from altered fatty acid oxidation enzyme expression in db/db mouse hearts.
In addition to the changes in myocardial energetics noted in this study, various other mechanisms by which SGLT2 inhibition confers cardiovascular benefits have been suggested (7, 8, 34) . These include indirect effects to improve filling conditions, through a reduction in preload and afterload, effects on attenuating the expression of cardiac sodiumhydrogen exchanger (NHE) (7, 8, 34, 35) , changes in adipokines, inflammatory biomarkers, natriuretic peptides, and epicardial adipose tissue volume (7).
Importantly, the benefits empagliflozin exert on cardiac function appear to be independent of hyperglycemia. In animal models of heart failure that do not factor in diabetes (induced by transverse aortic constriction), empagliflozin has been reported to prevent the decline in ejection fraction (11) . In this study, the benefits of empagliflozin were observed in addition to extrinsic factors that regulate cardiac function, such as hemodynamics and ketone oxidation, because these benefits were observed in the setting of matching preload and afterload, and in the presence of similar concentrations of insulin, fatty acids, glucose, or ketones. These data suggest that outcomes mediated by empagliflozin may be over and above indirect hemodynamic effects, a STUDY LIMITATIONS. First, we did not include an empagliflozin-treated C57BL/6J group because our primary focus was on the effects of empagliflozin in a diabetic setting. In future studies, the addition of an empagliflozin-treated C57BL/6J group would help assess whether empagliflozin increases cardiac glucose oxidation and fatty acid oxidation in a model in which glucose oxidation is not suppressed as in the db/db mouse heart. Second, we also did not include a C57BL/6J group in the ex vivo ketone study.
Accordingly, it would be important in future investigations to investigate the short-term effect of ketones in a healthy heart. Third, we used 5 mmol/l of glucose in the diabetic mouse heart perfusions.
This is subphysiological in a diabetic setting. However, 5 mmol/l glucose is within the normal glucose levels for both the healthy model and an empagliflozin-treated model, and was maintained throughout all groups for consistency. Finally, the concentration of insulin added to the ex vivo heart buffer 30 min after the initiation of perfusion was lower in the ex vivo ketone study versus the chronic empagliflozin feeding study, which should be considered when making comparisons between these 2 studies.
CONCLUSIONS
The present study provides important translational clues on the effects of empagliflozin on cardiac energetics in experimental diabetes. We conclude that the salutatory effects of SGLT2 inhibitors on cardiac failure may be, in part, due to an increase in cardiac ATP production via an increase in rates of cardiac oxidation of glucose and fatty acids, and increased supply and oxidation of ketones by the heart. We observed that overall rates of ketone oxidation were dramatically depressed in experimental diabetes, and remained unchanged with empagliflozin treatment, but could be increased by increasing ketone supply to the heart. This suggests that the ability of empagliflozin to increase circulating ketone levels may provide the heart with an additional source of energy to sustain contractile function. 
ADDRESS
SGLT2 Inhibition and Cardiac Bioenergetics in Diabetes
